We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Extended-Release Mixed Amphetamine Salts for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder: A Pilot, Randomized Double-Blind, Placebo-Controlled Trial.
- Authors
Levin, Frances R.; Mariani, John J.; Pavlicova, Martina; Choi, C. Jean; Basaraba, Cale; Mahony, Amy L.; Brooks, Daniel J.; Brezing, Christina A.; Naqvi, Nasir
- Abstract
Objective: To determine if treatment of co-occurring adult ADHD and Cannabis Use Disorder (CUD) with extended-release mixed amphetamine salts (MAS-ER) would be effective at improving ADHD symptoms and promoting abstinence. Method: A 12-week randomized, double-blind, two-arm pilot feasibility trial of adults with comorbid ADHD and CUD (n = 28) comparing MAS-ER (80 mg) to placebo. Main outcomes: ADHD: ≥30% symptom reduction, measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS). CUD: Abstinence during last 2 observed weeks of maintenance phase. Results: Overall, medication was well-tolerated. There was no significant difference in ADHD symptom reduction (MAS-ER: 83.3%; placebo: 71.4%; p =.65) or cannabis abstinence (MAS-ER: 15.4%; placebo: 0%; p =.27). MAS-ER group showed a significant decrease in weekly cannabis use days over time compared to placebo (p <.0001). Conclusions: MAS-ER was generally well-tolerated. The small sample size precluded a determination of MAS-ER's superiority reducing ADHD symptoms or promoting abstinence. Notably, MAS-ER significantly reduced weekly days of use over time.
- Subjects
MARIJUANA abuse; TEMPERANCE; SUBSTANCE abuse; ATTENTION-deficit hyperactivity disorder; ADULTS
- Publication
Journal of Attention Disorders, 2024, Vol 28, Issue 11, p1467
- ISSN
1087-0547
- Publication type
Article
- DOI
10.1177/10870547241264675